Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Fair value with moderate growth potential.
Share Price & News
How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IART's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IART underperformed the US Medical Equipment industry which returned -4.5% over the past year.
Return vs Market: IART underperformed the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWhat Does Integra LifeSciences Holdings Corporation's (NASDAQ:IART) P/E Ratio Tell You?
3 weeks ago | Simply Wall StCan You Imagine How Integra LifeSciences Holdings's (NASDAQ:IART) Shareholders Feel About The 70% Share Price Increase?
Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IART ($44.58) is trading below our estimate of fair value ($65.85)
Significantly Below Fair Value: IART is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IART is poor value based on its PE Ratio (76x) compared to the Medical Equipment industry average (39x).
PE vs Market: IART is poor value based on its PE Ratio (76x) compared to the US market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: IART is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: IART is good value based on its PB Ratio (2.7x) compared to the US Medical Equipment industry average (3x).
How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IART's forecast earnings growth (36.3% per year) is above the savings rate (1.7%).
Earnings vs Market: IART's earnings (36.3% per year) are forecast to grow faster than the US market (12.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IART's revenue (4.4% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: IART's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IART's Return on Equity is forecast to be low in 3 years time (16.8%).
How has Integra LifeSciences Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IART has a large one-off loss of $161.6M impacting its December 31 2019 financial results.
Growing Profit Margin: IART's current net profit margins (3.3%) are lower than last year (4.1%).
Past Earnings Growth Analysis
Earnings Trend: IART's earnings have grown by 19.8% per year over the past 5 years.
Accelerating Growth: IART's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IART had negative earnings growth (-17.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (1%).
Return on Equity
High ROE: IART's Return on Equity (3.5%) is considered low.
How is Integra LifeSciences Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IART's short term assets ($858.2M) exceed its short term liabilities ($331.3M).
Long Term Liabilities: IART's short term assets ($858.2M) do not cover its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: IART's debt to equity ratio (98.3%) is considered high.
Reducing Debt: IART's debt to equity ratio has increased from 89.6% to 98.3% over the past 5 years.
Debt Coverage: IART's debt is not well covered by operating cash flow (16.6%).
Interest Coverage: IART's interest payments on its debt are well covered by EBIT (6x coverage).
Inventory Level: IART has a high level of physical assets or inventory.
Debt Coverage by Assets: IART's debt is not covered by short term assets (assets are 0.6x debt).
What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pete Arduini (54yo)
Mr. Peter J. Arduini, also known as Pete, has been Chief Executive Officer and President at Derma Sciences, Inc. since February 2017. Mr. Arduini has been the Chief Executive Officer of Integra LifeScience ...
CEO Compensation Analysis
Compensation vs Market: Pete's total compensation ($USD7.65M) is above average for companies of similar size in the US market ($USD5.53M).
Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.
|COO & Corporate VP of International||0.83yr||US$2.29m||0.060% $2.3m|
|Corporate VP||1.42yrs||US$1.14m||0.039% $1.5m|
|Corporate VP & President of Specialty Surgical Solutions||3.33yrs||US$1.82m||0.051% $1.9m|
|Corporate VP and President of Orthopedics & Tissue Technologies||7.33yrs||US$1.37m||0.053% $2.0m|
|Founder and Chairman Emeritus||2.92yrs||US$37.50k||0.16% $6.0m|
|Corporate VP||0.83yr||no data||0.043% $1.6m|
|VP, Principal Accounting Officer & Corporate Controller||2.5yrs||no data||0.0094% $355.3k|
|Corporate VP & Chief Scientific Officer||6.17yrs||no data||0.018% $674.4k|
|Chief Information Officer & Senior VP||no data||no data||no data|
Experienced Management: IART's management team is considered experienced (3.3 years average tenure).
|Founder and Chairman Emeritus||2.92yrs||US$37.50k||0.16% $6.0m|
|Independent Director||11yrs||US$282.58k||0.083% $3.1m|
|Independent Director||6.67yrs||US$270.03k||0.052% $2.0m|
|Independent Director||14.25yrs||US$280.03k||0.044% $1.7m|
|Presiding Director||1.58yrs||US$275.14k||0.081% $3.1m|
|Independent Director||28.25yrs||US$275.08k||0.053% $2.0m|
|Independent Director||1.25yrs||no data||0.012% $436.8k|
|Independent Director||7.08yrs||US$265.08k||0.047% $1.8m|
Experienced Board: IART's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.4%.
Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources
- Name: Integra LifeSciences Holdings Corporation
- Ticker: IART
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.772b
- Shares outstanding: 84.44m
- Website: https://www.integralife.com
Number of Employees
- Integra LifeSciences Holdings Corporation
- 1100 Campus Road
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IART||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 1995|
|IL3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 1995|
|IL3||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Aug 1995|
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it sells hardware products, such as bone and joint fixation, and joint replacement devices; and implants and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was founded in 1989 and is headquartered in Princeton, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 05:28|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.